ArticleIn vivo (Athens, Greece)
Over-expression of Truncated IK Ameliorates Dinitrochlorobenzene-Induced Allergic Contact Dermatitis Lesions in BALB/c Mice.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimAllergic contact dermatitis (ACD) is a delayed-type hypersensitivity reaction mediated by hapten-specific T cells. Dinitrochlorobenzene (DNCB)-induced mouse models are widely used to investigate the pathogenesis of contact dermatitis. Inhibitor K562 (IK) cytokine suppresses IFN-γ-induced MHC class II expression on B cells by increasing cAMP levels. Previously, we reported that truncated IK (tIK) expression in transgenic (Tg) mice ameliorated rheumatoid arthritis by suppressing CD4 MATERIALS AND
methodsACD was induced in BALB/c and tIK Tg mice through repeated DNCB application. Ear thickness and scratching behavior were assessed. Serum IgE levels and mast cell-associated gene expression were analyzed. Th cell differentiation was evaluated using flow cytometry. PSA, an experimental model used to study systemic allergic reactions, was induced by IgE sensitization followed by antigen challenge, and hypothermia, serum IgE, and mast cell activation were measured.
resultsDNCB-treated BALB/c mice developed severe dermatitis, including increased ear thickness and scratching behavior, whereas tIK Tg mice exhibited milder symptoms. tIK over-expression also led to lower serum IgE levels and reduced mast cell-associated gene expression. T cell analysis revealed suppressed Th2 and Th17 differentiation, while Tregs and Th1 cells remained unaffected. Beyond ACD, tIK Tg mice exhibited attenuated PSA responses, with less severe hypothermia, lower serum IgE levels, and reduced mast cell activation compared to wild-type controls.
conclusiontIK suppresses both localized and systemic hypersensitivity by modulating Th cell differentiation and mast cell activity. tIK may serve as a potential therapeutic target for allergic and inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.